<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346970</url>
  </required_header>
  <id_info>
    <org_study_id>2005-005694-30</org_study_id>
    <nct_id>NCT00346970</nct_id>
  </id_info>
  <brief_title>The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)</brief_title>
  <official_title>Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <brief_summary>
    <textblock>
      The aim of the present study is to characterize novel mechanisms whereby HDL may exert potent
      vasculoprotective effects independent of reverse cholesterol transport, in particular the
      effect of HDL on the regulation of the vascular NAD(P)H oxidase enzyme system, a major
      vascular source of superoxide, known to be important for endothelial dysfunction. In
      addition, the present study will characterize the effect of HDL on endothelial progenitor
      cell (EPC) mobilization, nitric oxide production and in vivo regenerative capacity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antioxidative Properties of Endothelial Progenitor Cells</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FDD</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (HDL) Elevation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended-release Niacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended-Release Niacin</intervention_name>
    <description>Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Statin treatment for at least 3 weeks

          -  Reduced HDL: &lt; 40 mg/dL (1.03 mmol/L) in men or &lt; 50 mg/dL (1.29 mmol/L) in women

          -  Plus TWO of the following (thereby defining the patients to have metabolic syndrome
             (Grundy et al.; Circulation 2005)):

          -  Elevated waist circumference: ≥ 102 cm (≥ 40 inches) in men or ≥ 88 cm (≥ 35 inches)
             in women

          -  Elevated triglycerides: ≥ 150 mg/dL (1.7 mmol/L

          -  Elevated blood pressure: ≥ 130 mmHg systolic blood pressure or ≥ 80 mmHg diastolic
             blood pressure or anti-hypertensive treatment

          -  Elevated fasting glucose: ≥ 100 mg/dL or on drug treatment for elevated fasting
             glucose

        Exclusion Criteria:

          -  Hypersensitivity to niacin

          -  Active liver disease or impaired liver function

          -  Persistent elevation of transaminases

          -  Cholestasis

          -  Gastric ulcer

          -  Acute coronary syndrome

          -  Gout

          -  Pregnancy, lactation

          -  Active infections

          -  Cancer

          -  Untreated concomitant diseases

          -  Renal insufficiency or renal failure

          -  Hypothyreosis

          -  Alcoholism

          -  Myopathies

          -  Muscle pain under therapy with fibrates or statins

          -  Hereditary muscle diseases in family history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmut Drexler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulf Landmesser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sajoscha A Sorrentino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>May 5, 2008</last_update_submitted>
  <last_update_submitted_qc>May 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2008</last_update_posted>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>High Density Lipoprotein</keyword>
  <keyword>Extended-Release Niacin</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Endothelial Progenitor Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

